ReviewDrugs & aging2013
Do statins have a role in the prevention of age-related macular degeneration?
Review in Drugs & aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration.PloS one · 2013Trial
- Associations of systemic health and medication use with the enlargement rate of geographic atrophy in age-related macular degeneration.The British journal of ophthalmology · 2023Article
- The Relationship between Statin and Risk of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.Journal of ophthalmology · 2022Review
- Statins and the progression of age-related macular degeneration in the United States.PloS one · 2021Article
- Incidence and Risk Factors of Reticular Pseudodrusen Using Multimodal Imaging.JAMA ophthalmology · 2020Article
- The Question of a Role for Statins in Age-Related Macular Degeneration.International journal of molecular sciences · 2018Review
- Retinal Cholesterol Content Is Reduced in Simvastatin-Treated Mice Due to Inhibited Local Biosynthesis Albeit Increased Uptake of Serum Cholesterol.Drug metabolism and disposition: the biological fate of chemicals · 2018Article
- Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies.Investigative ophthalmology & visual science · 2018Review
- Cholesterol in mouse retina originates primarily from in situ de novo biosynthesis.Journal of lipid research · 2016Article
- Cholesterol in the retina: the best is yet to come.Progress in retinal and eye research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is a leading cause of blindness worldwide for which preventative therapies are few. Evidence suggesting shared common risk factors and mirrored pathophysiology between cardiovascular disease and AMD led to the hypothesis that hydroxymethylglutaryl-CoA reductase inhibitors (statins) could be helpful in preventing AMD. For over a decade, observational studies have repeatedly investigated this hypothesis with conflicting conclusions. Although many reports conclude that statin use has no effect on the risk of AMD, no randomized controlled trial has yet been completed. Furthermore, relatively few studies factor characteristics of statin use into their analysis. A few studies have observed an incompletely explained protective effect against drusen, a funduscopic finding associated with AMD. Although there is insufficient evidence for a preventive effect of statins on dry AMD, there does seem to be stronger evidence against any effect on the development of exudative AMD. Overall, we find that there is insufficient evidence to conclude whether statin use is helpful in preventing AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.